Buy Cadonilimab | Cadonilimab supplier | purchase Cadonilimab | Cadonilimab cost | Cadonilimab manufacturer | order Cadonilimab | Cadonilimab distributor CAS: 2394841-59-7

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
There is no price information at the moment, you can send an inquiry,and we will reply to you as soon as possible.

Size

Availability

Price(USD)

VIP Price (USD)

Quantity

There is no price information at the moment, you can send an inquiry,and we will reply to you as soon as possible.

Product Overview

Product Name	Anti-Human PD-1xCTLA-4 Bispecific Antibody(Cadonilimab)
CAS	2394841-59-7
Storage condition	-80°C for one-year storage. Avoid repeated freeze-thaw.

Product details

Cadonilimab is a pioneering bispecific antibody targeting PD-1 and CTLA-4,it blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Related literature

Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice.

PMID: 38677243 DOI: 10.1016/j.biopha.2024.116669

Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab.

PMID: 37600791 PMCID: PMC10435079 DOI: 10.3389/fimmu.2023.1188523

Antibodies to watch in 2022.

PMID: 35030985 PMCID: PMC8765076 DOI: 10.1080/19420862.2021.2014296

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies.

PMID: 34577584 PMCID: PMC8468026 DOI: 10.3390/ph14090884

Sorry, no related items

History

CLA1494